Another explanation may be that sitagliptin protects hepatocytes by increasing the systemic GLP-1 level, which binds the GLP-1 receptor on hepatocytes, resulting in reduced hepatic insulin resistance and steatosis [32,40,41]. The gene discussed is GLP1R; the disease is steatosis.